Michael Davis

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk is advising Amwell on its agreement to form a multi-year, strategic partnership with Google Cloud to deliver transformative telehealth solutions across the global healthcare…

Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and future success-based milestone payments. The transaction is…

We advised an ad hoc group of term lenders in connection with the comprehensive recapitalization

Davis Polk is advising Kyocera Corporation in connection with its proposed acquisition of the shares of common stock of AVX Corporation not already owned by Kyocera for $21.75 per share or…

Davis Polk advised an ad hoc group of lenders under Fusion Connect, Inc.’s prepetition secured first-lien credit facility in the chapter 11 restructuring of Fusion Connect, Inc. and certain…

Davis Polk is advising Varagon Capital Partners, L.P. on its agreement to form a new strategic partnership with Aflac Global Investments and the extension of its existing strategic…

Davis Polk advised Crestview Partners on its minority investment in ICM Partners, LLC.Founded in 2004, Crestview is a value-oriented private equity firm focused on the middle market…

Davis Polk is advising Bertelsmann SE & Co. KGaA on its $675 million acquisition of the stake it did not hold in Penguin Random House. Bertelsmann acquired the remaining 25% stake held…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…